Home
User Guide
What's in a MalaCard Search Guide Our Sources
Analysis Tools
GeneCards GeneAnalytics GeneAlaCart PathCards VarElect
Release Notes Disease Lists/Categories
About
About MalaCards Datasets Our Publications Weizmann Institute LifeMap Discovery® Terms of Use MalaCards Team
BLC
MCID: BLD134
MIFTS: 74

Bladder Cancer (BLC)

Categories: Blood diseases, Cancer diseases, Genetic diseases, Nephrological diseases, Rare diseases
Data Licensing
For inquiries, contact:
[email protected]
Genes Variations Tissues Related diseases Publications Symptoms & Phenotypes Drugs
Sources

Aliases & Classifications for Bladder Cancer

About this section

MalaCards integrated aliases for Bladder Cancer:

Name: Bladder Cancer 57 11 19 42 73 12 53 41 14 36 75
Urinary Bladder Cancer 11 73 5 14 33
Urinary Bladder Carcinoma 42 28 5
Bladder Carcinoma 11 53 14
Bladder Neoplasm 75 28 71
Malignant Neoplasm of Urinary Bladder 71 33
Carcinoma of Bladder 71 33
Cancer, Bladder 42 38
Bladder Tumor 42 16
Malignant Neoplasm of Bladder, Part Unspecified 33
Primary Malignant Neoplasm of Bladder 33
Urothelial Carcinoma of the Bladder 73
Malignant Tumour of Urinary Bladder 33
Neoplasm of the Urinary Bladder 42
Cancer of the Urinary Bladder 42
Carcinoma of Urinary Bladder 11
Tumor of the Urinary Bladder 42
Malignant Bladder Neoplasm 42
Bladder Carcinoma Urinary 42
Urinary Bladder Neoplasms 43
Urinary Bladder Neoplasm 42
Bladder Cancer, Somatic 57
Cancer, Urinary Bladder 42
Malignant Bladder Tumor 42
Neoplasm of the Bladder 42
Tumor of the Bladder 11
Bladder Cancer Nos 33
Vesical Cancer Nos 33
Bladder Tumors 53
Blc 73

Characteristics:


Inheritance:

Somatic mutation 57

Classifications:

MalaCards categories:
Global: Genetic diseases Rare diseases Cancer diseases
Anatomical: Nephrological diseases Blood diseases
See all MalaCards categories (disease lists)
ICD10: 31
ICD11: 33


External Ids:

Disease Ontology 11 DOID:11054 DOID:4007
OMIM® 57 109800
ICD9CM 34 188
MeSH 43 D001749
ICD10 31 C67 C67.9
MedGen 40 C0005684
SNOMED-CT via HPO 69 255109008
UMLS 71 C0005684 C0005695 C0699885
Sources

Summaries for Bladder Cancer

About this section

MedlinePlus Genetics: 42 Bladder cancer is a disease in which certain cells in the bladder become abnormal and multiply uncontrollably to form a tumor. The bladder is a muscular organ in the lower abdomen that stores urine until it can be removed (excreted) from the body.Bladder cancer may cause blood in the urine, pain during urination, frequent urination, the feeling of needing to urinate without being able to, or lower back pain. Many of these signs and symptoms are nonspecific, which means they may occur in multiple disorders. People who have one or more of these nonspecific health problems often do not have bladder cancer, but have another condition such as an infection.Bladder cancer develops when tumors form in the tissue that lines the bladder. There are several types of bladder cancer, categorized by the type of cell in the tissue that becomes cancerous. The most common type is transitional cell carcinoma (also known as urothelial carcinoma); others include squamous cell carcinoma and adenocarcinoma. If the tumor spreads  (metastasizes) beyond the lining of the bladder into nearby tissues or organs, it is known as invasive bladder cancer.

MalaCards based summary: Bladder Cancer, also known as urinary bladder cancer, is related to bladder urothelial carcinoma and costello syndrome. An important gene associated with Bladder Cancer is FGFR3 (Fibroblast Growth Factor Receptor 3), and among its related pathways/superpathways are Breast cancer pathway and MAPK Signaling: Mitogens. The drugs Tamsulosin and Lornoxicam have been mentioned in the context of this disorder. Affiliated tissues include urinary bladder, lymph node and prostate, and related phenotypes are transitional cell carcinoma of the bladder and bladder neoplasm

MedlinePlus: 41 The bladder is a hollow organ in your lower abdomen that stores urine. Bladder cancer occurs in the lining of the bladder. It is the sixth most common type of cancer in the United States. Symptoms include: Blood in your urine A frequent urge to urinate Pain when you urinate Low back pain Risk factors for developing bladder cancer include smoking and exposure to certain chemicals in the workplace. People with a family history of bladder cancer or who are older, white, or male have a higher risk. Treatments for bladder cancer include surgery, radiation therapy, chemotherapy, and biologic therapy. Biologic therapy boosts your body's own ability to fight cancer. NIH: National Cancer Institute

UniProtKB/Swiss-Prot: 73 A malignancy originating in tissues of the urinary bladder. It often presents with multiple tumors appearing at different times and at different sites in the bladder. Most bladder cancers are transitional cell carcinomas that begin in cells that normally make up the inner lining of the bladder. Other types of bladder cancer include squamous cell carcinoma (cancer that begins in thin, flat cells) and adenocarcinoma (cancer that begins in cells that make and release mucus and other fluids). Bladder cancer is a complex disorder with both genetic and environmental influences.

Disease Ontology 11 Urinary bladder cancer: An urinary system cancer that results in malignant growth located in the urinary bladder.

Bladder carcinoma: A urinary bladder cancer that has material basis in abnormally proliferating cells derives from epithelial cells.

Wikipedia: 75 Bladder cancer is any of several types of cancer arising from the tissues of the urinary bladder.... more...

More information from OMIM: 109800
Sources

Related Diseases for Bladder Cancer

About this section

Diseases in the Bladder Cancer family:

Bladder Carcinoma in Situ

Diseases related to Bladder Cancer via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 1327)
# Related Disease Score Top Affiliating Genes
1 bladder urothelial carcinoma 32.8 TUG1 RB1 PVT1 LRRC56 KRAS HRAS
2 costello syndrome 32.5 LRRC56 KRAS HRAS
3 bladder disease 32.5 MIR221 MIR21 MIR143 MIR10B
4 squamous cell carcinoma 32.1 UCA1 TUG1 RB1 KRAS HRAS HOTAIR
5 prostate cancer 32.0 UCA1 TUG1 RB1 PVT1 MIR221 MIR21
6 adenocarcinoma 31.9 RB1 KRAS HRAS H19 FGFR3
7 lung cancer 31.9 ZEB2-AS1 UCA1 TUG1 RB1 PVT1 MIR221
8 renal cell carcinoma, nonpapillary 31.8 UCA1 TUG1 PVT1 MIR221 MIR21 MIR143
9 kidney cancer 31.7 PVT1 MIR21 HOTAIR H19
10 colorectal cancer 31.7 UCA1 TUG1 RB1 PVT1 MIR221 MIR21
11 gallbladder cancer 31.6 UCA1 TUG1 RB1 MIR143 KRAS HRAS
12 lung cancer susceptibility 3 31.6 TUG1 RB1 MIR21 MIR143 LRRC56 KRAS
13 hepatocellular carcinoma 31.5 ZEB2-AS1 UCA1 TUG1 RB1 PVT1 MIR221
14 breast cancer 31.5 UCA1 TUG1 RB1 PVT1 MIR221 MIR21
15 endometrial cancer 31.5 UCA1 TUG1 RB1 MIR21 KRAS HRAS
16 gastric cancer 31.5 UCA1 TUG1 RB1 PVT1 MIR221 MIR21
17 melanoma 31.5 UCA1 RB1 PVT1 MIR221 MIR21 MIR127
18 cervical cancer 31.5 UCA1 TUG1 RB1 PVT1 MIR221 MIR21
19 ovarian cancer 31.5 UCA1 TUG1 RB1 PVT1 MIR221 MIR21
20 glioblastoma 31.4 TUG1 RB1 MIR221 MIR21 MIR10B LRRC56
21 pancreatic cancer 31.4 UCA1 TUG1 RB1 PVT1 MIR221 MIR21
22 suppression of tumorigenicity 12 31.4 MIR221 LRRC56 HRAS
23 urinary system disease 31.4 MIR221 MIR21 MIR143 MIR127
24 esophageal cancer 31.4 UCA1 RB1 PVT1 MIR221 MIR21 MIR143
25 non-invasive bladder papillary urothelial neoplasm 31.3 FGFR3 BRINP1
26 myeloma, multiple 31.3 UCA1 TUG1 RB1 PVT1 MIR221 MIR21
27 rectum cancer 31.3 MIR221 MIR21 MIR143 KRAS HRAS
28 rhabdomyosarcoma 31.3 RB1 LRRC56 KRAS HRAS H19 FGFR3
29 osteogenic sarcoma 31.3 UCA1 TUG1 RB1 PVT1 HOTAIR H19
30 squamous cell carcinoma, head and neck 31.2 RB1 MIR221 MIR21 MIR143 MIR10B LRRC56
31 rectal benign neoplasm 31.2 MIR143 KRAS HRAS
32 head and neck cancer 31.2 MIR221 MIR21 MIR143 MIR127 MIR10B KRAS
33 colonic benign neoplasm 31.2 MIR21 MIR143 KRAS HRAS
34 cholangiocarcinoma 31.2 UCA1 TUG1 MIR21 KRAS H19
35 lip and oral cavity cancer 31.1 RB1 MIR21 LRRC56 HRAS
36 small cell cancer of the lung 31.1 TUG1 RB1 MIR21 HOTAIR
37 lymphatic system disease 31.1 MIR221 MIR21 MIR143 MIR127
38 bladder urachal carcinoma 31.1 KRAS HRAS
39 bladder transitional cell papilloma 31.1 HRAS FGFR3
40 thyroid carcinoma 31.1 UCA1 PVT1 HOTAIR H19
41 retinitis pigmentosa 11 31.1 UCA1 TUG1 PVT1 HOTAIR
42 lung squamous cell carcinoma 31.1 TUG1 RB1 PVT1 LRRC56 KRAS HRAS
43 peripheral nervous system disease 31.0 MIR21 MIR143 MIR127 KRAS HRAS
44 leukemia, chronic myeloid 31.0 UCA1 MIR127 KRAS HRAS HOTAIR H19
45 hematologic cancer 31.0 RB1 PVT1 MIR221 MIR21 MIR143 MIR127
46 pancreatic ductal adenocarcinoma 31.0 UCA1 PVT1 MIR221 MIR21 MIR143 MIR10B
47 brain cancer 31.0 RB1 MIR221 MIR21 MIR143 MIR10B
48 lung benign neoplasm 31.0 RB1 KRAS HRAS
49 leukemia, acute lymphoblastic 31.0 RB1 MIR221 MIR21 KRAS HRAS
50 body mass index quantitative trait locus 11 31.0 MIR221 MIR21 MIR143 MIR127 MIR10B H19

Comorbidity relations with Bladder Cancer via Phenotypic Disease Network (PDN): (show all 18)


Acute Cystitis Acute Kidney Failure
Bladder Neck Obstruction Chronic Kidney Disease
Cystitis Cystitis Cystica
Deficiency Anemia Hydronephrosis
Neutropenia Paralytic Ileus
Prostate Cancer Prostatic Hypertrophy
Radiation Cystitis Renal Pelvis Carcinoma
Ureter, Cancer of Urethral Benign Neoplasm
Urethral Stricture Urinary Tract Obstruction

Graphical network of the top 20 diseases related to Bladder Cancer:



Diseases related to Bladder Cancer
Sources

Symptoms & Phenotypes for Bladder Cancer

About this section

Human phenotypes related to Bladder Cancer:

30
# Description HPO Frequency Orphanet Frequency HPO Source Accession
1 transitional cell carcinoma of the bladder 30 HP:0006740
2 bladder neoplasm 30 HP:0009725

Symptoms via clinical synopsis from OMIM®:

57 (Updated 08-Dec-2022)
Neoplasia:
bladder cancer
transitional cell bladder carcinoma

Clinical features from OMIM®:

109800 (Updated 08-Dec-2022)

MGI Mouse Phenotypes related to Bladder Cancer:

45
# Description MGI Source Accession Score Top Affiliating Genes
1 no phenotypic analysis MP:0003012 9.23 BRINP1 FGFR3 HOTAIR HRAS KRAS MIR10B
Sources

Drugs & Therapeutics for Bladder Cancer

About this section

Drugs for Bladder Cancer (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 515)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Tamsulosin Approved, Investigational Phase 4 106133-20-4 129211
2
Lornoxicam Approved, Investigational Phase 4 70374-39-9 5282204 54690031
3
Lidocaine Approved, Vet_approved Phase 4 137-58-6 3676
4
Diclofenac Approved, Vet_approved Phase 4 15307-86-5, 15307-79-6 3033
5
Midazolam Approved, Illicit Phase 4 59467-70-8 4192
6
Nicotine Approved Phase 4 54-11-5 942 89594
7
Bupropion Approved Phase 4 31677-93-7, 34841-39-9, 34911-55-2 444
8
Dopamine Approved Phase 4 62-31-7, 51-61-6 681
9
Alverine Approved, Investigational Phase 4 150-59-4 3678
10
Mebeverine Approved, Investigational Phase 4 3625-06-7 4031
11
Neostigmine Approved, Vet_approved Phase 4 59-99-4 4456 5824
12
Glycopyrronium Approved, Investigational, Vet_approved Phase 4 596-51-0, 740028-90-4 3494
13
Mepivacaine Approved, Vet_approved Phase 4 96-88-8, 1722-62-9 4062
14
Levoleucovorin Approved, Experimental, Investigational Phase 4 68538-85-2, 58-05-9, 73951-54-9 149436 6006
15
Rocuronium Approved Phase 4 119302-91-9, 143558-00-3 441290
16
Benzocaine Approved, Investigational Phase 4 1994-09-7, 94-09-7 2337
17
Tannic acid Approved Phase 4 1401-55-4 16129878 16129778
18
Cisatracurium Approved, Investigational Phase 4 96946-41-7 62887
19
Remifentanil Approved Phase 4 132875-61-7 60815
20
Sufentanil Approved, Investigational Phase 4 56030-54-7 41693
21
Levofloxacin Approved, Investigational Phase 4 100986-85-4 149096
22
Ofloxacin Approved Phase 4 82419-36-1 4583
23
Ertapenem Approved, Investigational Phase 4 153832-46-3 150610
24
Nitrofurantoin Approved, Vet_approved Phase 4 67-20-9 5353830
25
Trimethoprim Approved, Vet_approved Phase 4 738-70-5 5578
26
Sulfamethoxazole Approved Phase 4 723-46-6 5329
27
Clindamycin Approved, Vet_approved Phase 4 18323-44-9, 24729-96-2 29029
28
Fentanyl Approved, Illicit, Investigational, Vet_approved Phase 4 437-38-7 3345
29
Droperidol Approved, Vet_approved Phase 4 548-73-2 3168
30
Acetylsalicylic acid Approved, Vet_approved Phase 4 50-78-2 2244
31
Folic acid Approved, Nutraceutical, Vet_approved Phase 4 59-30-3 6037
32 Omega 3 Fatty Acid Phase 4
33 Analgesics, Opioid Phase 4
34 Narcotics Phase 4
35 Adrenergic alpha-Antagonists Phase 4
36 Adrenergic alpha-1 Receptor Antagonists Phase 4
37 Anti-Arrhythmia Agents Phase 4
38
Solifenacin Succinate Phase 4 242478-38-2 216457
39 Anti-Anxiety Agents Phase 4
40 Sodium Channel Blockers Phase 4
41 Diuretics, Potassium Sparing Phase 4
42 GABA Modulators Phase 4
43 Cephalosporins Phase 4
44 Anesthetics Phase 4
45 Neuromuscular Nondepolarizing Agents Phase 4
46 Neuromuscular Blocking Agents Phase 4
47 Anesthetics, Local Phase 4
48 Cholinergic Antagonists Phase 4
49 Cholinergic Agents Phase 4
50 Psychotropic Drugs Phase 4

Interventional clinical trials:

(show top 50) (show all 1390)
# Name Status NCT ID Phase Drugs
1 The Effects of Sequential Mitomycin and Bacillus Calmette-Guérin Treatment Versus Bacillus Calmette-Guérin Monotherapy in Patients With High Risk Non-Muscle Invasive Bladder Cancer Unknown status NCT03790384 Phase 4 Mitomycin
2 Chemoradiotherapy for Recurrent T1G3 Bladder Cancer After BCG Failure Unknown status NCT03274284 Phase 4
3 Comparison of Medical and Surgical Treatments of Benign Prostate Hyperplasia in Patients Who Have Low Grade Non Muscle Invasive Bladder Cancer for Tumour Recurrence and Progression Unknown status NCT02443844 Phase 4 Tamsulosin
4 Solifenacin vs Levofloxacin vs Lornoxicam for Management of Intravesical Instillation of Bacillus Calmette-Guerin (BCG) Side Effects A Single Blinded Randomised Controlled Study Unknown status NCT03038321 Phase 4 sofenacin;Tavanic;Xefo
5 The Effect of Preemptive Analgesia On The Comfort Of Patient and Doctor, in Cystoscopy Unknown status NCT03831321 Phase 4 Diclofenac Sodium;Lubricant Gel
6 Comparison of the Pathological Stage and Clinical Outcome of en Bloc Transurethral Resection by HybridKnife or Laser Versus Conventional Transurethral Resection for NMIBC: a Prospective, Single Centre, Randomized Study Unknown status NCT03221062 Phase 4
7 Influence of Immune Nutrition Diet on 90-Day Outcomes in Patients Undergoing Radical Cystectomy and Bladder Substitutions: A Randomized Controlled Trial Unknown status NCT03147586 Phase 4 Bio-tech and omega-3 plus;placebo
8 The Assessment of Postoperative Cognitive Dysfunction After Transurethral Resection of Bladder Tumor Under Spinal Anesthesia Unknown status NCT03029676 Phase 4 benzodiazepines;opioid
9 Ultrasound-Guided Obturator Nerve Block for Transurethral Procedures - Interadductor Approach Unknown status NCT02696733 Phase 4 lidocaine 2%;0.9% Natrium Chloratum with a 2nd generation cephalosporin
10 Comparation the Effect of C-LMA and I-gel in Regurgitation and Postoperative Complications Unknown status NCT01876836 Phase 4
11 In the Prediction of Recurrence and Progression of NMIBC; EORTC or CUETO or Both? Completed NCT03174912 Phase 4
12 The Effect of Neuromuscular Blockade During Transurethral Resection of Bladder Cancer on Surgical Condition and Recovery Profiles : A Prospective, Randomized and Controlled Trial Completed NCT03039543 Phase 4 Rocuronium;Sugammadex
13 Effect of TachoSil® on Incidence of Symptomatic and Radiographic Lymphoceles After Extended Pelvic Lymph Node Dissection in Prostate and Bladder Cancer. Completed NCT02001857 Phase 4 1 TachoSil hemostatic sponge (9,5 cm x 4,8 cm) placed on each side on the external iliac artery.
14 The Value of Immediate Post-operative Intravesical Epirubicin Instillation in Intermediate and High Risk Non Muscle Invasive Bladder Cancer (NMIBC): A Randomized Controlled Trial Completed NCT02214602 Phase 4 Epirubicin
15 Enhancing Tobacco Use Treatment for African American Light Smokers Completed NCT00666978 Phase 4 bupropion hydrochloride
16 Comparing the Lozenge to the Patch for Smoking Cessation Completed NCT00365508 Phase 4 nicotine lozenge;nicotine patch
17 Mebeverine For Daytime And Nocturnal Incontinence and After Orthotopic W-Ileal Neobladders - Assessment Of Efficacy And Quality Of Life Effect Within 1 Year Post-Surgery: A Randomized Controlled Study Completed NCT03147599 Phase 4 Coloverin;Placebo
18 A Phase IV Investigation of Sugammadex in Outpatient Urological Procedures Completed NCT03138967 Phase 4 Rocuronium;Sugammadex;Neostigmine;Glycopyrrolate
19 Comparison of Obturator Nerve Blockade and Neuromuscular Blockade for the Prevention of Adductor Spasm in Patients Undergoing Transurethral Resection of Bladder Tumors. Completed NCT03063255 Phase 4 Obturator block;Neuromuscular block
20 Impact of Remimazolam Tosilate for General Anesthesia on Prognosis After Bladder Cancer Surgery: a Randomized Controlled Trial Recruiting NCT04532606 Phase 4 Remimazolam;Propofol
21 Does Prophylactic Antibiotic Decrease the Rate of Urinary Tract Infection After Robot Assisted Radical Cystectomy Recruiting NCT04502095 Phase 4 Clindamycin;Ertapenem;Levofloxacin;Nitrofurantoin;Trimethoprim-Sulfamethoxazole
22 An Open Label, Randomized Control Study of Probiotics Administration in the Immunotherapy of Urothelial Bladder Carcinoma Recruiting NCT05220124 Phase 4 Live Combined (Bifidobacterium,Lactobacillus and Enterococcus Capsules)
23 Low-dose Neuroleptanalgesia Reduce the Occurrences of Postoperative Delirium in Elderly Patients Undergoing Non-cardiac Major Surgery : a Randomized Controlled Trial Recruiting NCT05068180 Phase 4 low-dose neuroleptanalgesia;Placebo
24 Neoadjuvant Short-term Intensive Chemoresection Versus Standard Adjuvant Intravesical Instillations in NMIBC Active, not recruiting NCT03348969 Phase 4 Mitomycin c
25 A Prospective, Single Center Clinical Study to Examine the Safety and Efficacy of BCG Combined With Tislelizumab as Treatment for BCG-untreated Patients With High-grade Non-muscle-invasive Bladder Cancer Not yet recruiting NCT05580354 Phase 4 BCG combined with Tislelizumab
26 A Clinical Study of Disitamab Vedotin for Injection Combined With Penpulimab Injection in Neoadjuvant Therapy for Patients With HER2-expressing Cisplatin-intolerant cT2-T4aNxM0 Bladder Urothelial Carcinoma Not yet recruiting NCT05488353 Phase 4 Disitamab Vedotin for Injection,Penpulimab Injection
27 Must Aspirin be Discontinued Prior to TURBT: a Prospective, Randomized, Non-inferiority Trial Comparing Peri-operative Aspirin Continuation Versus Discontinuation. Terminated NCT02350543 Phase 4 Aspirin
28 Recurrence of Bladder Cancer After Transurethral Resection With Hexvix Withdrawn NCT00785694 Phase 4 hexaminolevulinate
29 Bladder Cancer Prognosis Programme (Incorporating SELENIB Trial) [TREATMENT] Unknown status NCT00553345 Phase 3 selenium;vitamin E
30 A Study of Comparing Effects of Thulium Laser en Bloc Resection and Electrical Transurethral Resection of the Non-muscle Invasive Bladder Cancer Unknown status NCT02951078 Phase 3
31 Adjuvant Chemotherapy Following Radical Cystectomy to Treat Locally Advanced Bladder Cancer Unknown status NCT02074189 Phase 3 Gemcitabine, Cisplatin
32 The Efficacy of Distilled Water vs Mitomycin C as a Single Dose Immediate Instillation After Transurethral Resection of Intermediate Risk, Recurrent Superficial Bladder Cancer Unknown status NCT00816075 Phase 2, Phase 3 distilled water
33 Bladder Cancer Prognosis Programme (Incorporating SELENIB Trial) Unknown status NCT00553124 Phase 3 selenium;vitamin E
34 Phase III Study Of Adjuvant Cisplatin-Gemcitabine Vs. Observation After Radical Cystectomy In High-Risk Bladder Cancer Unknown status NCT00054626 Phase 3 cisplatin;gemcitabine hydrochloride
35 Study of the Efficacy of Maintenance Therapy by UFT or BCG for Superficial Bladder Cancer Against Recurrence in Urological Oncology Council of Northern Tokyo: EMBARK Study Unknown status NCT01082510 Phase 3 Bacille Calmette-Guerin;uracil-tegafur
36 Treatment of Ta Bladder Cancer in High Risk of Recurrence - Fluorescence Cystoscopy With Optimized Adjuvant Mitomycin-C (FinnBladder 9) Unknown status NCT01675219 Phase 3 optimized MMC;single immediate chemotherapy instillation
37 Determining the Specificity and Sensitivity of the BladderLight™ Assay as a Diagnostic and Risk Stratification Tool for Bladder Cancer Unknown status NCT03427034 Phase 2, Phase 3
38 HYMN: A Randomized Controlled Phase III Trial Comparing Hyperthermia Plus Mitomycin to a Second Course of Bacillus Calmette-Guerin or Standard Therapy in Patients With Recurrence of Non-Muscle Invasive Bladder Cancer Following Induction or Maintenance Bacillus Calmette-Guerin Therapy Unknown status NCT01094964 Phase 3 epirubicin hydrochloride;mitomycin C
39 Adjuvant Intraarterial Chemotherapy Following Surgery in Treating Patients With Locally Advanced Bladder Cancer Unknown status NCT01627197 Phase 3
40 A Phase II/III, Randomised, Two-Arm, Comparison of Maintenance Lapatinib Versus Placebo After First-Line Chemotherapy in Patients With HER1 and/or HER2 Overexpressing Locally Advanced or Metastatic Bladder Cancer [LaMB] Unknown status NCT00949455 Phase 2, Phase 3 lapatinib ditosylate
41 Role of Geriatric Intervention in Treatment of Older Patients With Cancer : a Phase III Randomized Study (PREPARE) Unknown status NCT02704832 Phase 3
42 Four Cycles of Cisplatin-Based Chemotherapy in Metastatic Urothelial Carcinoma Compared to Six Cycles: Randomized Phase III Trial - FOCUS Study - Unknown status NCT03296306 Phase 3 Treatment duration of cisplatin based chemotherapy
43 Phase III Randomized Study of a Single Adjunctive Instillation of Intravesical AD 32 (N-Trifluoroacetyladriamycin-14-valerate) Versus No Adjunctive Therapy Immediately Following Transurethral Resection in Patients With Multiple Superficial (Ta/T1) Bladder Tumors Unknown status NCT00003725 Phase 3 valrubicin
44 Adjuvant vs. Progression-Triggered Treatment With Gemcitabine After Radical Cystectomy for Locally Advanced Transitional Cell Carcinoma of the Bladder in Patients Not Suitable for Cisplatin-Based Chemotherapy - A Phase 3 Study Unknown status NCT00146276 Phase 3 gemcitabine
45 Randomized Double-Blind Controlled Phase III Trial of Hyperbaric Oxygen Therapy in Patients Suffering Long-Term Adverse Effects of Radiotherapy for Pelvic Cancer (HOT II) Unknown status NCT01087268 Phase 3
46 A Prospective Randomized Phase III Trial of Maintenance Pemetrexed Versus Observation in Patients With Recurrent or Metastatic Urothelial Carcinoma Who Completed First Line Platinum-based Chemotherapy Without Disease Progression Unknown status NCT03193788 Phase 3 pemetrexed;Folic Acid;Vitamin B12 Injection;Dexamethasone
47 Efficacy of Diclofenac Suppositories in Prevention of Immediate Side Effects of BCG Bladder Irrigations. A Double Blind Placebo Controlled Randomized Study Unknown status NCT01542567 Phase 3 Abitren;Placebo
48 A Randomized, Multicenter, Open-label, Phase 3 Study to Compare the Efficacy and Safety of GEMOX(Gemcitabine/Oxaliplatin) vs XELOX(Xeloda/Oxaliplatin) in Advanced Biliary Tract Carcinoma Unknown status NCT01470443 Phase 3 Oxaliplatin
49 Holmium Versus Bipolar en Bloc Transurethral Resection of Urothelium Tumor of the Urinary Bladder: A Randomized Controlled Trial Unknown status NCT04576286 Phase 3
50 A Prospective, Open-label Randomized Clinical Trial of a Single Bladder Instillation of Mitomycin C vs. Gemcitabine vs. No Additional Treatment Immediately After Transurethral Resection of Bladder Tumor (TURBT) Unknown status NCT02695771 Phase 3 Mitomycin C;Gemcitabine

Search NIH Clinical Center for Bladder Cancer

Inferred drug relations via UMLS 71 / NDF-RT 50 :


BCG Vaccine
Carboplatin
Cisplatin
CISPLATIN PWDR
doxorubicin hydrochloride liposome
Etoposide
etoposide phosphate
pembrolizumab
Thiotepa

Cell-based therapeutics:


LifeMap Discovery
Data from LifeMap, the Embryonic Development and Stem Cells Database
Read about Bladder Cancer cell therapies at LifeMap Discovery.
Stem-cell-based therapeutic approaches for Bladder Cancer:
Neo-Urinary Conduit, smooth muscle cell 3D culture for bladder diseases
Embryonic/Adult Cultured Cells Related to Bladder Cancer:
Neo-Urinary Conduit PMIDs: 22136657

Cochrane evidence based reviews: urinary bladder neoplasms

Sources

Genetic Tests for Bladder Cancer

About this section

Genetic tests related to Bladder Cancer:

# Genetic test Affiliating Genes
1 Urinary Bladder Carcinoma 28
2 Bladder Neoplasm 28
Sources

Anatomical Context for Bladder Cancer

About this section

Organs/tissues related to Bladder Cancer:

FMA: Urinary Bladder
MalaCards : Lymph Node, Prostate, Lung, T Cells, Kidney, Spinal Cord, Endothelial
Sources

Publications for Bladder Cancer

About this section

Articles related to Bladder Cancer:

(show top 50) (show all 43594)
# Title Authors PMID Year
1
Frequent activating mutations of FGFR3 in human bladder and cervix carcinomas. 57 5
10471491 1999
2
Antibody-based targeting of FGFR3 in bladder carcinoma and t(4;14)-positive multiple myeloma in mice. 53 62 5
19381019 2009
3
MPDL3280A (anti-PD-L1) treatment leads to clinical activity in metastatic bladder cancer. 62 57
25428503 2014
4
Recurrent inactivation of STAG2 in bladder cancer is not associated with aneuploidy. 62 57
24121791 2013
5
Whole-genome and whole-exome sequencing of bladder cancer identifies frequent alterations in genes involved in sister chromatid cohesion and segregation. 62 57
24121792 2013
6
Frequent truncating mutations of STAG2 in bladder cancer. 62 57
24121789 2013
7
Genome sequencing identifies a basis for everolimus sensitivity. 62 57
22923433 2012
8
Frequent mutations of chromatin remodeling genes in transitional cell carcinoma of the bladder. 62 57
21822268 2011
9
FGFR3 mutational status and protein expression in patients with bladder cancer in a Jordanian population. 62 5
20542753 2010
10
Risk of urothelial bladder cancer in Lynch syndrome is increased, in particular among MSH2 mutation carriers. 62 57
20591884 2010
11
A sequence variant at 4p16.3 confers susceptibility to urinary bladder cancer. 62 57
20348956 2010
12
Sequence variant on 8q24 confers susceptibility to urinary bladder cancer. 62 57
18794855 2008
13
Mitochondrial cytochrome B gene mutation promotes tumor growth in bladder cancer. 62 57
18245469 2008
14
Bladder cancer predisposition: a multigenic approach to DNA-repair and cell-cycle-control genes. 62 57
16465622 2006
15
Identifying distinct classes of bladder carcinoma using microarrays. 62 57
12469123 2003
16
Cytogenetics and molecular genetics of bladder cancer: a personal view. 62 57
12407698 2002
17
Familial transitional cell carcinoma. 62 57
8709350 1996
18
Slow N-acetylation genotype is a susceptibility factor in occupational and smoking related bladder cancer. 62 57
7757072 1995
19
Definition of two regions of deletion on chromosome 9 in carcinoma of the bladder. 62 57
8208555 1994
20
Loss of heterozygosity on chromosome 11p13 in primary bladder carcinoma. 62 57
8100210 1993
21
Clonal origin of bladder cancer. 62 57
1445507 1992
22
Frequent inactivation of the retinoblastoma anti-oncogene is restricted to a subset of human tumor cells. 53 5
2181449 1990
23
Allelic losses of chromosomes 9, 11, and 17 in human bladder cancer. 62 57
2293558 1990
24
Loss of genes on the short arm of chromosome 11 in bladder cancer. 62 5
2999610 1985
25
Oncogene from human EJ bladder carcinoma is located on the short arm of chromosome 11. 62 57
6297001 1983
26
Activation of the T24 bladder carcinoma transforming gene is linked to a single amino acid change. 62 5
7177195 1982
27
Isolation and preliminary characterization of a human transforming gene from T24 bladder carcinoma cells. 62 57
7063039 1982
28
Familial aggregation of urothelial carcinoma. 62 57
7053069 1981
29
Transforming genes of carcinomas and neuroblastomas introduced into mouse fibroblasts. 62 57
7207618 1981
30
Transforming activity of human tumor DNAs. 62 57
6940134 1981
31
Familial factors in bladder carcinoma. 62 57
480484 1979
32
Abnormal tryptophan metabolism in a family with a history of bladder cancer. 62 57
994212 1976
33
Photodynamic versus white-light-guided resection of first-diagnosis non-muscle-invasive bladder cancer: PHOTO RCT. 62 41
36300825 2022
34
Efficacy of long-term extended nursing services combined with atezolizumab in patients with bladder cancer after endoscopic bladder resection. 62 41
36197272 2022
35
Cancer. TERT promoter mutations and telomerase reactivation in urothelial cancer. 57
25722414 2015
36
Prospective enterprise-level molecular genotyping of a cohort of cancer patients. 5
25157968 2014
37
Keratinocytic epidermal nevi are associated with mosaic RAS mutations. 5
22499344 2012
38
MicroRNA-221 silencing predisposed human bladder cancer cells to undergo apoptosis induced by TRAIL. 62 46
19767219 2010
39
Up-regulation of microRNA in bladder tumor tissue is not common. 62 46
19475496 2010
40
A microRNA expression ratio defining the invasive phenotype in bladder tumors. 62 46
18799331 2010
41
Distinct microRNA alterations characterize high- and low-grade bladder cancer. 62 46
19843843 2009
42
MicroRNA expression profiling of human metastatic cancers identifies cancer gene targets. 53 46
19593777 2009
43
Identification of novel microRNA targets based on microRNA signatures in bladder cancer. 62 46
19378336 2009
44
Genomic profiling of microRNAs in bladder cancer: miR-129 is associated with poor outcome and promotes cell death in vitro. 62 46
19487295 2009
45
MicroRNA-143 as a tumor suppressor for bladder cancer. 62 46
19157460 2009
46
Acanthosis nigricans in a child with mild osteochondrodysplasia and K650Q mutation in the FGFR3 gene. 5
18000903 2007
47
Micro-RNA profiling in kidney and bladder cancers. 62 46
17826655 2007
48
Myopathy caused by HRAS germline mutations: implications for disturbed myogenic differentiation in the presence of constitutive HRas activation. 5
17412879 2007
49
Novel FGFR3 mutations creating cysteine residues in the extracellular domain of the receptor cause achondroplasia or severe forms of hypochondroplasia. 5
16912704 2006
50
Germline mutations in HRAS proto-oncogene cause Costello syndrome. 5
16170316 2005
Sources

Variations for Bladder Cancer

About this section

ClinVar genetic disease variations for Bladder Cancer:

5 (show top 50) (show all 97)
# Gene Name Type Significance ClinVarId dbSNP ID Position
1 MRE11 NM_005591.4(MRE11):c.*1359T>C SNV Other
 60639 rs397509348 GRCh37: 11:94151932-94151932
GRCh38: 11:94418766-94418766
2 MRE11 NM_005591.4(MRE11):c.*2731G>A SNV Other
 60640 rs397509349 GRCh37: 11:94150560-94150560
GRCh38: 11:94417394-94417394
3 MRE11 NM_005591.4(MRE11):c.*570A>C SNV Other
 60641 rs397509346 GRCh37: 11:94152721-94152721
GRCh38: 11:94419555-94419555
4 MRE11 NM_005591.4(MRE11):c.*631C>T SNV Other
 60642 rs397509347 GRCh37: 11:94152660-94152660
GRCh38: 11:94419494-94419494
5 MRE11 NM_005591.4(MRE11):c.-105-326A>T SNV Other
 60643 rs183829476 GRCh37: 11:94226398-94226398
GRCh38: 11:94493232-94493232
6 MRE11 NM_005591.4(MRE11):c.-105-387C>T SNV Other
 60644 rs397509350 GRCh37: 11:94226459-94226459
GRCh38: 11:94493293-94493293
7 MRE11 NM_005591.4(MRE11):c.1098+1177G>A SNV Other
 60645 rs369782842 GRCh37: 11:94199802-94199802
GRCh38: 11:94466636-94466636
8 MRE11 NM_005591.4(MRE11):c.1098+1408A>G SNV Other
 60646 rs200367125 GRCh37: 11:94199571-94199571
GRCh38: 11:94466405-94466405
9 MRE11 NM_005591.4(MRE11):c.1098+1620T>C SNV Other
 60647 rs397509352 GRCh37: 11:94199359-94199359
GRCh38: 11:94466193-94466193
10 MRE11 NM_005591.4(MRE11):c.1098+614C>T SNV Other
 60648 rs140067184 GRCh37: 11:94200365-94200365
GRCh38: 11:94467199-94467199
11 MRE11 NM_005591.4(MRE11):c.1225+40T>C SNV Other
 60650 rs192979170 GRCh37: 11:94197239-94197239
GRCh38: 11:94464073-94464073
12 MRE11 NM_005591.4(MRE11):c.1225+572A>T SNV Other
 60651 rs397509353 GRCh37: 11:94196707-94196707
GRCh38: 11:94463541-94463541
13 MRE11 NM_005591.4(MRE11):c.1225+577A>C SNV Other
 60652 rs397509354 GRCh37: 11:94196702-94196702
GRCh38: 11:94463536-94463536
14 MRE11 NM_005591.4(MRE11):c.1225+605T>C SNV Other
 60653 rs397509355 GRCh37: 11:94196674-94196674
GRCh38: 11:94463508-94463508
15 MRE11 NM_005591.4(MRE11):c.1225+804T>C SNV Other
 60654 rs397509356 GRCh37: 11:94196475-94196475
GRCh38: 11:94463309-94463309
16 MRE11 NM_005591.4(MRE11):c.1327-461A>C SNV Other
 60655 rs185485357 GRCh37: 11:94193208-94193208
GRCh38: 11:94460042-94460042
17 MRE11 NM_005591.4(MRE11):c.1783+561G>A SNV Other
 60656 rs397509357 GRCh37: 11:94179824-94179824
GRCh38: 11:94446658-94446658
18 MRE11 NM_005591.4(MRE11):c.1784-438A>G SNV Other
 60657 rs397509358 GRCh37: 11:94179497-94179497
GRCh38: 11:94446331-94446331
19 MRE11 NM_005591.4(MRE11):c.20+821G>A SNV Other
 60658 rs397509351 GRCh37: 11:94225127-94225127
GRCh38: 11:94491961-94491961
20 MRE11 NM_005591.4(MRE11):c.314+99A>G SNV Other
 60659 rs143677623 GRCh37: 11:94218991-94218991
GRCh38: 11:94485825-94485825
21 MRE11 NM_005591.4(MRE11):c.545-297G>T SNV Other
 60660 rs118024137 GRCh37: 11:94209866-94209866
GRCh38: 11:94476700-94476700
22 MRE11 NM_005591.4(MRE11):c.1563+281G>A SNV Other
 60672 rs397509429 GRCh37: 11:94189161-94189161
GRCh38: 11:94455995-94455995
23 MRE11 NM_005591.4(MRE11):c.1202A>G (p.His401Arg) SNV Other
 60649 rs146779325 GRCh37: 11:94197302-94197302
GRCh38: 11:94464136-94464136
24 RB1 NM_000321.3(RB1):c.2663+2T>C SNV Pathogenic
 126807 rs587778839 GRCh37: 13:49050981-49050981
GRCh38: 13:48476845-48476845
25 HRAS, LRRC56 NM_005343.4(HRAS):c.37G>T (p.Gly13Cys) SNV Pathogenic
 12606 rs104894228 GRCh37: 11:534286-534286
GRCh38: 11:534286-534286
26 HRAS, LRRC56 NM_005343.4(HRAS):c.35G>C (p.Gly12Ala) SNV Pathogenic
 12603 rs104894230 GRCh37: 11:534288-534288
GRCh38: 11:534288-534288
27 HRAS, LRRC56 NM_005343.4(HRAS):c.34G>T (p.Gly12Cys) SNV Pathogenic
Likely Pathogenic
 12613 rs104894229 GRCh37: 11:534289-534289
GRCh38: 11:534289-534289
28 HRAS, LRRC56 NM_005343.4(HRAS):c.179G>T (p.Gly60Val) SNV Pathogenic
 391700 rs730880460 GRCh37: 11:533877-533877
GRCh38: 11:533877-533877
29 KRAS NM_004985.5(KRAS):c.34G>C (p.Gly12Arg) SNV Pathogenic
 12579 rs121913530 GRCh37: 12:25398285-25398285
GRCh38: 12:25245351-25245351
30 FGFR3 NM_000142.5(FGFR3):c.746C>G (p.Ser249Cys) SNV Pathogenic
Pathogenic
Likely Pathogenic
 16339 rs121913483 GRCh37: 4:1803568-1803568
GRCh38: 4:1801841-1801841
31 RB1 NM_000321.3(RB1):c.1970dup (p.Ala658fs) DUP Pathogenic
 1686121 GRCh37: 13:49033832-49033833
GRCh38: 13:48459696-48459697
32 FGFR3 NM_000142.5(FGFR3):c.1948A>C (p.Lys650Gln) SNV Pathogenic
Likely Pathogenic
 16348 rs78311289 GRCh37: 4:1807889-1807889
GRCh38: 4:1806162-1806162
33 FGFR3 NM_000142.5(FGFR3):c.742C>T (p.Arg248Cys) SNV Pathogenic
 16332 rs121913482 GRCh37: 4:1803564-1803564
GRCh38: 4:1801837-1801837
34 FGFR3 NM_000142.5(FGFR3):c.749C>G (p.Pro250Arg) SNV Pathogenic
 16340 rs4647924 GRCh37: 4:1803571-1803571
GRCh38: 4:1801844-1801844
35 FGFR3 NM_000142.5(FGFR3):c.1138G>A (p.Gly380Arg) SNV Pathogenic
 16327 rs28931614 GRCh37: 4:1806119-1806119
GRCh38: 4:1804392-1804392
36 FGFR3 NM_000142.5(FGFR3):c.1620C>G (p.Asn540Lys) SNV Pathogenic
 16338 rs28933068 GRCh37: 4:1807371-1807371
GRCh38: 4:1805644-1805644
37 FGFR3 NM_000142.5(FGFR3):c.1949A>C (p.Lys650Thr) SNV Pathogenic
 65855 rs121913105 GRCh37: 4:1807890-1807890
GRCh38: 4:1806163-1806163
38 KRAS NM_004985.5(KRAS):c.458A>T (p.Asp153Val) SNV Pathogenic
 12587 rs104894360 GRCh37: 12:25362838-25362838
GRCh38: 12:25209904-25209904
39 RB1 NM_000321.3(RB1):c.1215+1G>A SNV Pathogenic
 126832 rs587776783 GRCh37: 13:48947629-48947629
GRCh38: 13:48373493-48373493
40 RB1 NM_000321.3(RB1):c.1981C>T (p.Arg661Trp) SNV Pathogenic
 13087 rs137853294 GRCh37: 13:49033844-49033844
GRCh38: 13:48459708-48459708
41 RB1 NM_000321.3(RB1):c.2107-2A>G SNV Pathogenic
 13077 rs1593538130 GRCh37: 13:49037865-49037865
GRCh38: 13:48463729-48463729
42 HRAS, LRRC56 NM_005343.4(HRAS):c.35G>T (p.Gly12Val) SNV Pathogenic
 12600 rs104894230 GRCh37: 11:534288-534288
GRCh38: 11:534288-534288
43 FGFR3 NM_000142.5(FGFR3):c.2089G>T (p.Gly697Cys) SNV Likely Pathogenic
 376248 rs121913480 GRCh37: 4:1808331-1808331
GRCh38: 4:1806604-1806604
44 CTNNA3 NM_013266.4(CTNNA3):c.2568del (p.Lys856fs) DEL Likely Pathogenic
 1700649 GRCh37: 10:67680208-67680208
GRCh38: 10:65920450-65920450
45 FGFR3 NM_000142.5(FGFR3):c.1111A>T (p.Ser371Cys) SNV Likely Pathogenic
 16333 rs121913484 GRCh37: 4:1806092-1806092
GRCh38: 4:1804365-1804365
46 FGFR3 NM_000142.5(FGFR3):c.1118A>G (p.Tyr373Cys) SNV Likely Pathogenic
 16342 rs121913485 GRCh37: 4:1806099-1806099
GRCh38: 4:1804372-1804372
47 FGFR3 NM_000142.5(FGFR3):c.1108G>T (p.Gly370Cys) SNV Likely Pathogenic
 16359 rs121913479 GRCh37: 4:1806089-1806089
GRCh38: 4:1804362-1804362
48 RB1 NM_000321.3(RB1):c.381-2A>T SNV Likely Pathogenic
 1685421 GRCh37: 13:48919214-48919214
GRCh38: 13:48345078-48345078
49 RB1 NM_000321.3(RB1):c.2490-1530_*109del DEL Likely Pathogenic
 1685422 GRCh37: 13:49045964-49054314
GRCh38: 13:48471828-48480178
50 FGFR3 NM_000142.5(FGFR3):c.200G>A (p.Gly67Asp) SNV Uncertain Significance
 546226 rs369232922 GRCh37: 4:1801071-1801071
GRCh38: 4:1799344-1799344

UniProtKB/Swiss-Prot genetic disease variations for Bladder Cancer:

73
# Symbol AA change Variation ID SNP ID
1 FGFR3 p.Arg248Cys VAR_004148 rs121913482
2 FGFR3 p.Ser249Cys VAR_004149 rs121913483
3 FGFR3 p.Gly370Cys VAR_004151 rs121913479
4 FGFR3 p.Lys650Glu VAR_004160 rs78311289
5 FGFR3 p.Lys650Gln VAR_018390 rs78311289

Copy number variations for Bladder Cancer from CNVD:

6 (show top 50) (show all 98)
# CNVD ID Chromosome Start End Type Gene Symbol CNVD Disease
1 36534 1 77068898 77170790 Loss Bladder cancer
2 51778 11 130615965 132678521 Loss Bladder cancer
3 53648 11 31517796 32050223 Loss Bladder cancer
4 80757 13 97270228 100084626 Gain Bladder cancer
5 81341 14 101619009 102408085 Loss Bladder cancer
6 83177 14 19364851 19446107 Loss Bladder cancer
7 87829 14 77750645 79747731 Loss Bladder cancer
8 88246 14 88632756 89467875 Gain Bladder cancer
9 89915 15 19427350 19427409 Loss Bladder cancer
10 96847 15 95052889 95403459 Loss Bladder cancer
11 97491 16 10647794 11795463 Gain Bladder cancer
12 98997 16 22221235 32532138 Gain Bladder cancer
13 101674 16 45413780 45607724 Gain Bladder cancer
14 101856 16 46548299 69323131 Loss Bladder cancer
15 107647 17 1649595 1725887 Loss Bladder cancer
16 109050 17 24000000 38100000 Gain Bladder cancer
17 109225 17 24641926 27576519 Gain Bladder cancer
18 112300 17 38521264 78444637 Gain Bladder cancer
19 118108 17 7571719 7590863 Loss TP53 Bladder cancer
20 121742 18 467310 796252 Gain Bladder cancer
21 122814 18 61643142 67432063 Loss Bladder cancer
22 126424 19 18749534 19294814 Gain Bladder cancer
23 127148 19 278073 12616127 Gain Bladder cancer
24 127869 19 37856935 63485510 Gain Bladder cancer
25 135679 2 11956730 12796508 Gain Bladder cancer
26 135959 2 123437325 126399586 Loss Bladder cancer
27 138231 2 159948195 160120757 Loss Bladder cancer
28 141850 2 217249378 242464793 Loss Bladder cancer
29 146581 2 51236117 51635693 Loss Bladder cancer
30 148163 2 74469 50579433 Loss Bladder cancer
31 150320 2 9872881 10505097 Gain Bladder cancer
32 150974 20 157771 456225 Gain Bladder cancer
33 151125 20 17870221 18440898 Gain Bladder cancer
34 151502 20 22093371 26036562 Gain Bladder cancer
35 152003 20 28081598 47163674 Gain Bladder cancer
36 154726 20 48033501 54958791 Gain Bladder cancer
37 156571 20 61727753 62175139 Gain Bladder cancer
38 158507 21 33581851 34132794 Gain Bladder cancer
39 164078 22 34482413 35495073 Gain Bladder cancer
40 170412 3 153906953 155170944 Gain Bladder cancer
41 170822 3 159876217 162162404 Gain Bladder cancer
42 171019 3 162425422 164314793 Gain Bladder cancer
43 176797 3 50653920 52539982 Loss Bladder cancer
44 179967 4 1 4500000 Loss Bladder cancer
45 186746 4 38697312 42182524 Loss Bladder cancer
46 193888 5 134523261 135051953 Loss Bladder cancer
47 200115 5 50094582 74360979 Loss Bladder cancer
48 202946 5 90316808 90788310 Loss Bladder cancer
49 203715 6 1 61000000 Gain Bladder cancer
50 204149 6 107127877 107503845 Loss Bladder cancer
Sources

Expression for Bladder Cancer

About this section
Search GEO for disease gene expression data for Bladder Cancer.
Sources

Pathways for Bladder Cancer

About this section

Pathways related to Bladder Cancer according to GeneCards Suite gene sharing:

# Super pathways Score Top Affiliating Genes
1
Breast cancer pathway 74
Show member pathways
 12.14 RB1 KRAS HRAS FGFR3
2
MAPK Signaling: Mitogens 65
Show member pathways
 11.94 RB1 KRAS HRAS FGFR3
3
miRNAs involved in DNA damage response 74
11.37 MIR221 MIR21 MIR143
4
Vemurafenib Pathway, Pharmacodynamics 60
11.13 KRAS HRAS FGFR3
5
Head and neck squamous cell carcinoma 74
11.12 RB1 KRAS HRAS FGFR3
6
Aryl hydrocarbon receptor pathway 74
10.91 RB1 KRAS HRAS
7
ncRNAs involved in STAT3 signaling in hepatocellular carcinoma 74
10.73 UCA1 MIR21
8
MNAR-PELP1 and Estrogen Receptor Interaction 64
10.69 RB1 KRAS HRAS
9
Bladder cancer 74
10.53 RB1 KRAS HRAS FGFR3
10
TNF-alpha signaling pathway 74
Show member pathways
 10.51 KRAS HRAS
Sources

GO Terms for Bladder Cancer

About this section

Cellular components related to Bladder Cancer according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 RISC complex GO:0016442 9.36 MIR221 MIR21 MIR143 MIR127 MIR10B H19

Biological processes related to Bladder Cancer according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 positive regulation of protein kinase B signaling GO:0051897 9.62 MIR221 MIR21 MIR143 H19
2 negative regulation of mitotic cell cycle GO:0045930 9.56 RB1 MIR21 BRINP1
3 miRNA-mediated gene silencing by inhibition of translation GO:0035278 9.54 MIR221 MIR21 MIR10B
4 negative regulation of interleukin-21 production GO:0032705 9.16 MIR221 MIR21
5 positive regulation of vascular associated smooth muscle cell migration GO:1904754 9.13 MIR221 MIR21 MIR143
6 negative regulation of superoxide dismutase activity GO:1901670 8.62 MIR21 H19

Molecular functions related to Bladder Cancer according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 mRNA 3'-UTR binding GO:0003730 9.26 MIR21 MIR143 MIR127 MIR10B
2 mRNA base-pairing translational repressor activity GO:1903231 9.02 MIR221 MIR21 MIR143 MIR127 MIR10B
Sources

Sources for Bladder Cancer

About this section
2 CDC
6 CNVD
8 Cosmic
9 dbSNP
10 DGIdb
16 EFO
17 ExPASy
18 FMA
19 GARD
27 GO
28 GTR
29 HMDB
30 HPO
31 ICD10
32 ICD10 via Orphanet
33 ICD11
34 ICD9CM
35 IUPHAR
36 LifeMap
38 LOVD
40 MedGen
43 MeSH
44 MESH via Orphanet
45 MGI
48 NCI
49 NCIt
50 NDF-RT
52 NINDS
53 Novoseek
55 ODiseA
56 OMIM via Orphanet
57 OMIM® (Updated 08-Dec-2022)
61 PubChem
62 PubMed
64 QIAGEN
69 SNOMED-CT via HPO
70 Tocris
71 UMLS
72 UMLS via Orphanet
The MalaCards human disease database index: 1-9 A B C D E F G H I J K L M N O P Q R S T U V W X Y Z
Content
Loading form....